1. Home
  2. CTNM vs BIGC Comparison

CTNM vs BIGC Comparison

Compare CTNM & BIGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • BIGC
  • Stock Information
  • Founded
  • CTNM 2009
  • BIGC 2009
  • Country
  • CTNM United States
  • BIGC United States
  • Employees
  • CTNM N/A
  • BIGC N/A
  • Industry
  • CTNM
  • BIGC Computer Software: Prepackaged Software
  • Sector
  • CTNM
  • BIGC Technology
  • Exchange
  • CTNM Nasdaq
  • BIGC Nasdaq
  • Market Cap
  • CTNM 453.0M
  • BIGC 432.3M
  • IPO Year
  • CTNM 2024
  • BIGC 2020
  • Fundamental
  • Price
  • CTNM $17.21
  • BIGC $6.05
  • Analyst Decision
  • CTNM Strong Buy
  • BIGC Hold
  • Analyst Count
  • CTNM 4
  • BIGC 9
  • Target Price
  • CTNM $29.25
  • BIGC $8.61
  • AVG Volume (30 Days)
  • CTNM 74.8K
  • BIGC 899.4K
  • Earning Date
  • CTNM 11-06-2024
  • BIGC 11-07-2024
  • Dividend Yield
  • CTNM N/A
  • BIGC N/A
  • EPS Growth
  • CTNM N/A
  • BIGC N/A
  • EPS
  • CTNM N/A
  • BIGC N/A
  • Revenue
  • CTNM N/A
  • BIGC $330,048,000.00
  • Revenue This Year
  • CTNM N/A
  • BIGC $9.74
  • Revenue Next Year
  • CTNM N/A
  • BIGC $5.39
  • P/E Ratio
  • CTNM N/A
  • BIGC N/A
  • Revenue Growth
  • CTNM N/A
  • BIGC 10.87
  • 52 Week Low
  • CTNM $13.27
  • BIGC $5.13
  • 52 Week High
  • CTNM $22.00
  • BIGC $10.19
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • BIGC 55.16
  • Support Level
  • CTNM N/A
  • BIGC $5.13
  • Resistance Level
  • CTNM N/A
  • BIGC $6.83
  • Average True Range (ATR)
  • CTNM 0.00
  • BIGC 0.32
  • MACD
  • CTNM 0.00
  • BIGC 0.09
  • Stochastic Oscillator
  • CTNM 0.00
  • BIGC 51.25

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About BIGC BigCommerce Holdings Inc. Series 1

BigCommerce Holdings Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of revenue is generated from Americas-U.S.

Share on Social Networks: